Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02666053 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects
A Phase 1 study of Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT02666053 is a Phase 1 study of Infection, Human Immunodeficiency Virus that has completed, run by ViiV Healthcare. The registered enrollment target is 72 participants, below the 144-participant average among 19 other Infection, Human Immunodeficiency Virus trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02666053, a Phase 1 study of Infection, Human Immunodeficiency Virus, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to estimate the effect of high fat meal and increased gastric pH on BMS-663068 bioavailability
Conditions Studied
Interventions
- DRUG BMS-663068
Study Locations (1)
Texas
- GSK Investigational Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2016-01-27 |
| Est. Completion | 2016-02-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02666053
The ClinicalTrials.gov registry entry for NCT02666053 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 144-participant average among 19 other Infection, Human Immunodeficiency Virus trials with a reported enrollment target (50% lower). The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Infection, Human Immunodeficiency Virus appearing as the primary indexed condition, and to 1 intervention - of which BMS-663068 is the first listed.
NCT02666053 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02666053 about?
NCT02666053 is a clinical study titled "A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects". The purpose of this study is to estimate the effect of high fat meal and increased gastric pH on BMS-663068 bioavailability
What is the current status of trial NCT02666053?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2016-01-27. Estimated completion is 2016-02-22.
What conditions does trial NCT02666053 study?
This clinical trial studies the following conditions: Infection, Human Immunodeficiency Virus.
What interventions are being tested in trial NCT02666053?
The interventions under investigation include: BMS-663068 (DRUG).
Who is sponsoring clinical trial NCT02666053?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02666053 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infection, Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction
COMPLETED · Phase 1
-
Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine
COMPLETED · Phase 1
-
A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects
COMPLETED · Phase 1
-
A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)
COMPLETED · Phase 1
-
Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers
COMPLETED · Phase 1
-
Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.